Skip to Content
Merck
All Photos(3)

Key Documents

699800P

Avanti

MPLA (PHAD)

Avanti Research - A Croda Brand

Synonym(s):

PHAD phosphorylated hexaacyl disaccharide; Glycopyranoside Lipid A; GLA

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C96H184N3O22P
CAS Number:
Molecular Weight:
1763.47
UNSPSC Code:
12352211
NACRES:
NA.25

description

Monophosphoryl Lipid A (Synthetic) (PHAD)

Assay

>99% (HPLC)

form

powder

packaging

pkg of 1 × 1 mg (699800P-1mg)
pkg of 1 × 5 mg (699800P-5mg)

manufacturer/tradename

Avanti Research - A Croda Brand

application(s)

vaccine development

shipped in

dry ice

storage temp.

−20°C

General description

Monophosphoryl lipid A (MPLA) is either extracted from bacterial lipid A or by chemical synthesis.
Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Application

MPLA PHAD has been used:
  • as a component of cobalt porphyrin-phospholipid (Co-PoP) liposomes for the immunization of mice with membrane proximal external region (MPER) of the gp41 envelope protein
  • as an adjuvant along with dimethyldioctadecylammonium bromide(DDA) for C. muridarum recombinant membrane protein based multi-subunit vaccine
  • as toll-like receptor-4 (TLR4) agonist adjuvant for respiratory syncytial virus (RSV) fusion (F) protein FI-RSV vaccine

Biochem/physiol Actions

Monophosphoryl lipid A (MPLA) is a natural agonist for the toll-like receptor-4 (TLR4). It is useful as an adjuvant in immunization. MPLA is a safe prophylactic agent and has immunotherapeutic applications. MPLA used in vaccination improves B cell and T cell-mediated immunity.

Packaging

2 mL Amber Glass Crimp Cap Vial (699800P-1mg)
2 mL Amber Glass Crimp Cap Vial (699800P-5mg)

Other Notes

For R&D use only. Not for drug, household, or other uses.

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC
PHAD is a trademark of Avanti Polar Lipids, LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ryan C Anderson et al.
Colloids and surfaces. B, Biointerfaces, 75(1), 123-132 (2009-09-15)
Immunostimulatory molecules such as monophosphoryl lipid A (MPL), a Toll-like receptor 4 (TLR4) agonist, can be formulated to enhance vaccine adjuvant effects and to promote a Th1-type immune response. This study compares the in vitro and in vivo potency of
Caroline Boudousquié et al.
Vaccines, 8(1) (2020-01-18)
With the emergence of immune checkpoint inhibitors and adoptive T-cell therapies, there is a considerable interest in using personalized autologous dendritic cell (DC) vaccines in combination with T cell-targeting immunotherapies to potentially maximize the therapeutic impact of DC vaccines. Here
Christopher B Fox et al.
Sub-cellular biochemistry, 53, 303-321 (2010-07-02)
Natural derivatives and synthetic analogues of lipopolysaccharide are potent stimulators of the mammalian immune system. Retained adjuvant activity with reduced toxicity was obtained by the development of monophosphoryl lipid A (MPL((R))), which is approved for use in several vaccine products.
The TLR4 agonist monophosphoryl lipid a drives broad resistance to infection via dynamic reprogramming of macrophage metabolism
Fensterheim BA, et al.
Journal of Immunology, 200(11), 3777-3789 (2018)
Rhea N Coler et al.
PloS one, 5(10), e13677-e13677 (2010-11-10)
Safe, effective adjuvants that enhance vaccine potency, including induction of neutralizing Abs against a broad range of variant strains, is an important strategy for the development of seasonal influenza vaccines which can provide optimal protection, even during seasons when available

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service